NRx Pharmaceuticals, Inc. (NRXP) Stock Forecast
NRXP analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 4 analysts
- Price target
- $38.50 average of analyst targets
- Upside to target
- +1,380.8% from the latest close
- Next earnings
- November 13, 2026 EPS estimate $-0.29
- 52-week range
- $1.68 – $4.62
NRXP analyst ratings
4 analystsNumber of analysts at each rating.
NRXP price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
NRXP earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.15 | −$0.15 | −$0.15 | −$0.51 | +70.4% | 1 |
| Current fiscal year (2026) | −$0.80 | −$0.80 | −$0.80 | −$1.34 | +40.3% | 1 |
| Next fiscal year (2027) | −$0.35 | −$0.35 | −$0.35 | −$0.80 | +56.2% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
NRXP revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $1.3M | $1.2M | $1.5M | +431.1% | 3 |
| Current fiscal year (2026) | $5.6M | $4.3M | $8.2M | +357.9% | 4 |
| Next fiscal year (2027) | $90.2M | $6.0M | $279.2M | +1,507.3% | 4 |
NRXP EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
NRXP revenue: reported and forecast
NRXP EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.08 | −$0.08 | −$0.08 | −$0.08 | −$0.15 | +87.5% | 0 up · 1 down |
| Current fiscal year (2026) | −$0.36 | −$0.36 | −$0.36 | −$0.36 | −$0.80 | +122.2% | 0 up · 1 down |
| Next fiscal year (2027) | $0.50 | $0.50 | $0.50 | $0.50 | −$0.35 | −170.0% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
NRXP earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; NRXP beat in 6 of 12.
What analysts expect from NRXP
4 analysts cover NRx Pharmaceuticals; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $38.50, 1,380.8% above the latest close of $2.60. Analysts expect earnings of −$0.80 per share for 2026, +40.3% from a year earlier. For 2027 the average estimate is −$0.35 per share on revenue of $90.2 million. NRx Pharmaceuticals beat the EPS estimate in 6 of the last 12 quarters.
Related: NRXP income statement, NRXP key metrics, NRXP chart. See the NRXP stock overview for the latest quote and news.
NRXP forecast FAQ
What is NRx Pharmaceuticals's price target?
The average analyst price target for NRx Pharmaceuticals is $38.50, 1,380.8% above the latest close of $2.60.
Is NRx Pharmaceuticals a buy, hold or sell?
Of 4 analysts covering NRx Pharmaceuticals, 4 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is NRx Pharmaceuticals's EPS forecast?
Analysts forecast −$0.80 per share for 2026 (range −$0.80 to −$0.80); for 2027 the estimate is −$0.35.
What is NRx Pharmaceuticals's revenue forecast?
The average revenue estimate for 2026 is $5.6 million, growth of 357.9%; for 2027 it is $90.2 million.
When does NRx Pharmaceuticals report earnings?
NRx Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 13, 2026; the EPS estimate is $-0.29.
Does NRx Pharmaceuticals usually beat earnings estimates?
NRx Pharmaceuticals reported EPS at or above the analyst estimate in 6 of the last 12 quarters.